Analyst Price Target is $16.56
▲ +65.31% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for BioCryst Pharmaceuticals in the last 3 months. The average price target is $16.56, with a high forecast of $30.00 and a low forecast of $11.00. The average price target represents a 65.31% upside from the last price of $10.02.
Current Consensus is
Moderate Buy
The current consensus among 9 polled investment analysts is to moderate buy stock in BioCryst Pharmaceuticals. This rating has held steady since July 2024, when it changed from a Buy consensus rating.
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More
